Targeting HSP90 as a therapeutic approach for endometriosis: insights from proteomic analysis.
Endometriosis, a chronic inflammatory condition characterized by pain and infertility, remains a clinical challenge. Current hormonal and surgical treatments are often limited by side effects and high recurrence rates. In …
Shared Decision Making among Patients with Chronic Conditions in France: A Cross-Sectional Survey in the ComPaRe E-Cohort.
BackgroundShared decision making (SDM) is a cornerstone of patient-centered care; however, little information is available on how SDM is practiced in routine care. We aimed to assess the level of …
Efficacy and Safety of Traditional Chinese Medicine Retention Enema for Endometriosis: A Systematic Review and Meta-Analysis.
Background/Objectives: Herbal retention enema is widely used in Traditional Chinese Medicine for the management of endometriosis; however, its clinical efficacy and safety have not been systematically evaluated. Methods: Ten electronic …
Ionic liquid-coated gold core polymeric nanoparticles for selective neutrophil hitchhiking towards endometriosis treatment.
Endometriosis is a chronic inflammatory gynecological condition that affects millions of women and people with uteri globally, with limited available treatments. In this work, we explore using ionic liquid (IL)-coated …
Safety, Pharmacokinetics, and Sex Hormone Suppression of LY01021 versus Relugolix: A Single- and Multiple-Dose Escalation Study.
LY01021 is a novel oral small-molecule gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of various sex hormone-dependent disorders. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), …
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer - BioSpace
Quebec first province to publicly reimburse Jemperli (dostarlimab for injection) plus chemotherapy via RAMQ for the treatment of all adult patients with primary advanced or first recurrent endometrial cancer BioSpace